CO-ATLASEDGE
2.11.2021 10:02:06 CET | Business Wire | Press release
AtlasEdge, a pan-European edge data centre provider, has today announced the successful acquisition of twelve data centres. The deal is with Colt DCS, a world-class provider of Hyperscale data centres across Europe & APAC.
The successful acquisition from Colt strengthens AtlasEdge’s unique portfolio of distributed data centres that are positioned to support localised or low latency applications. AtlasEdge now operates more than 100 data centres across eleven countries in Europe, supporting more than 700 customers and providing connectivity to more than 50 different on-net carriers.
AtlasEdge provides a pan-European data centre portfolio that allows customers to design and configure their technology and network infrastructure to meet the growing requirements for lower latency, higher performance and localised solutions. With demand gravitating towards the edge of networks, AtlasEdge’s distributed and highly connected footprint provides a unique solution that is aligned with the next wave of growth in digital infrastructure.
This acquisition further expands AtlasEdge’s coverage and accelerates time to market in several new geographies, as well as establishing a collaboration between AtlasEdge and Colt Data Centre Services, with Colt Technology Services becoming an anchor tenant across multiple facilities. This network-neutral colocation strategy enables AtlasEdge’s customers to optimise their network routes, minimise their bandwidth costs and take advantage of the wide community of cloud, content, technology and enterprise companies present in the facilities.
The portfolio includes data centers in key tier one and tier two markets across Europe, including Amsterdam, Barcelona, Berlin, Brussels, Copenhagen, Hamburg, London, Madrid, Milan, Paris and Zurich.
“We are delighted to welcome these sites into our expanding portfolio,” commented Josh Joshi, Executive Chairman, AtlasEdge. “We are tapping into an exciting and emerging market where real time data traffic is growing and compute is gravitating to the edge of the network. As this demand builds, AtlasEdge is uniquely positioned to deliver seamless, localised and ultra-low latency digital infrastructure to our customers — from cloud providers to streaming services and enterprises. Our approach is open, carrier neutral and collaborative, and we look forward to working alongside Colt.”
Niclas Sanfridsson, CEO, Colt DCS, added, “Demand for data storage and cloud capabilities has never been higher, and so is the need for businesses to scale and find capacity. By restructuring and focusing on our hyperscale facilities, we can meet our customers’ needs on demand with true scalability and efficiency, while meeting their sustainability targets. We are committed to ensuring a sustainable business model for the future and this latest deal will improve the returns on investment across our portfolio, which can then be reinvested into the business.”
ABOUT AtlasEdge
AtlasEdge is a European edge data centre business with a mission to create Europe’s leading edge platform, delivering seamless, localised and ultra-low latency digital infrastructure to customers. Formed through a joint investment by Liberty Global, one of the world’s leading converged video, broadband and communications companies and DigitalBridge, a leading global investment firm dedicated to digital infrastructure, AtlasEdge already has an expanding portfolio of more than 100 data centres across the continent, providing proximity to the core network that is critical for the technology of tomorrow.
For more information, please visit www.atlasedge.com
ABOUT Colt DCS
Colt Data Centre Services provide true service and operational excellence in the sustainable design, build, delivery and operational management of hyperscale data centres across Europe and the APAC. We provide data centre solutions to hyperscale and large enterprise customers across 14 state of the art carrier neutral data centres spanning 8 cities. Our Hyperscale and colocation solutions allow our customers the freedom to plan effectively for the growth of their business, knowing that their data centre strategy is ready for the demands of tomorrow. We have over 25 years of experience in the industry, delivering on our vision of being the most trusted and customer centric data center operator in the market. We put environmental awareness at the heart of everything we do because we know it’s the right thing to do for our planet. That’s why we’re taking the ownership to reduce our environmental impact globally and make sustainability a key strategic driver. As part of our sustainability journey, alongside our sister company we are committed to achieving global net zero emissions for our own operations by 2030. https://www.coltdatacentres.net/
View source version on businesswire.com: https://www.businesswire.com/news/home/20211102005298/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom